Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Methylphenidate (MPH) is widely prescribed for adults with attention deficit hyperactivity disorder (ADHD), but data on long-term treatment and maintenance of effect are lacking. Osmotic release oral system-methylphenidate (OROS-MPH) was evaluated in a 52-wk open-label study in subjects who had previously completed a short-term placebo-controlled trial and short-term open-label extension. Efficacy was assessed using the investigator- and subject-rated Conners' Adult ADHD Rating Scales (CAARS:O-SV and CAARS:S-S), and the Clinical Global Impression - Severity (CGI-S), Sheehan Disability Scale (SDS) and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Subjects completing ≥52 wk of treatment were eligible for a 4-wk randomized, placebo-controlled withdrawal phase in which loss of treatment effect was assessed using CAARS:O-SV and CGI-S. In the open-label phase (n=156), mean CAARS:O-SV score decreased from baseline by 1.9±7.8 (p<0.01), and small, statistically significant improvements from baseline were observed for CAARS:S-S, CGI-S and SDS. In the double-blind phase (OROS-MPH, n=23; placebo, n=22), CAARS:O-SV increased from double-blind baseline in the OROS-MPH and placebo arms (4.0±7.6 vs. 6.5±7.8, not statistically significant). Long-term OROS-MPH treatment was well tolerated, and there was no evidence of withdrawal or rebound after discontinuation. In conclusion, the short-term benefits of OROS-MPH continue during long-term open-label treatment. Maintenance of efficacy in a placebo-controlled withdrawal design remains to be confirmed in larger patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928 · cited 1×
“Based on national and international guidelines as well as consensus statements, the treatment of choice for adults with ADHD is methylphenidate (MPH) (Kooij et al. 2010; National Collaborating Centre for Mental Health, 2009 ; Social and Health Directory, 2010).”
BackgroundSpencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385 · cited 4×
“Furthermore, OROS-MPH was well tolerated during the long-term open-label phase, with an adverseevent profile similar to other studies of MPH in adults with ADHD (Adler et al. 2011; Bouffard et al. 2003; Kooij et al. 2004; Medori et al. 2008; Spencer et al. 2005) and no new or unexpected adverse events were reported wi…”
BackgroundResultInfluentialMedori, R., Ramos-Quiroga, J. A., Casas, M., Kooij, J. J. S., Niemelä, A., Trott, G.-E., Lee, E., & Buitelaar, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.008 · Cited by 186 · cited 5×
“Subjects who initially entered the 5-wk, doubleblind, randomized, placebo-controlled, parallelgroup, fixed-dose LAMDA study (Medori et al. 2008) were eligible for a 7-wk open-label, flexible-dose extension if they completed the 5-wk double-blind phase or discontinued study medication due to poor…”
BackgroundMethodResultInfluentialSelf-citationKOOIJ, J. J. S., BURGER, H., BOONSTRA, A. M., VAN DER LINDEN, P. D., KALMA, L. E., & BUITELAAR, J. K. (2004) · Psychological Medicine · doi:10.1017/s0033291703001776 · Cited by 163 · cited 3×
“Furthermore, OROS-MPH was well tolerated during the long-term open-label phase, with an adverseevent profile similar to other studies of MPH in adults with ADHD (Adler et al. 2011; Bouffard et al. 2003; Kooij et al. 2004; Medori et al. 2008; Spencer et al. 2005) and no new or unexpected adverse events were reported wi…”
BackgroundResultSelf-citationAdler, L. A., Zimmerman, B., Starr, H. L., Silber, S., Palumbo, J., Orman, C., & Spencer, T. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a390ce · Cited by 106
Mick, E., Faraone, S. V., Spencer, T., Zhang, H. F., & Biederman, J. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707308468 · Cited by 95 · cited 1×
“The instrument is not diseasespecific and has been used in a number of clinical trials, including clinical trials in adults with ADHD, and sensitivity to treatment effects with MPH has been demonstrated (Mick et al. 2008).”
MethodWeisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94 · cited 1×
“In a 1-yr study of lisdexamfetamine dimesylate, for example, the completion rate was 55% (Weisler et al. 2009).”
BackgroundBouffard, R., Hechtman, L., Minde, K., & Iaboni-Kassab, F. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800806 · Cited by 81 · cited 3×
“Furthermore, OROS-MPH was well tolerated during the long-term open-label phase, with an adverseevent profile similar to other studies of MPH in adults with ADHD (Adler et al. 2011; Bouffard et al. 2003; Kooij et al. 2004; Medori et al. 2008; Spencer et al. 2005) and no new or unexpected adverse events were reported wi…”
BackgroundResult
Cited by
Horvath, J. C., Forte, J. D., & Carter, O. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2014.11.021 · Cited by 528
Puglia, M. H., Lillard, T. S., Morris, J. P., & Connelly, J. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422096112 · Cited by 216
Fredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.016 · Cited by 173
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders
Rubin, L. H., Carter, C. S., Bishop, J. R., Pournajafi-Nazarloo, H., Drogos, L. L., Hill, S. K., Ruocco, A. C., Keedy, S. K., Reilly, J. L., Keshavan, M. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu027 · Cited by 127
Marin, M.-F., Camprodon, J. A., Dougherty, D. D., & Milad, M. R. (2014) · Depression and Anxiety · doi:10.1002/da.22252 · Cited by 106
Metadata
- Authors
- Buitelaar, J. K., Trott, G.-E., Hofecker, M., Waechter, S., Berwaerts, J., Dejonkheere, J., & Schäuble, B.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-29
- Volume
- 15
- Issue
- 01
- Pages
- 1-13
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2136829534
- Cited by
- 112
- References
- 11
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. https://app.cochat.ai/papers/10.1017/s1461145711001131
- The paper
- Buitelaar, J. K., Trott, G.-E., Hofecker, M., Waechter, S., Berwaerts, J., Dejonkheere, J., & Schäuble, B. (2012). Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145711001131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.